New treatment option for adolescents with schizophrenia

The licensing of Invega (paliperidone) has been extended to include children from 15 years old with schizophrenia.

Extrapyramidal symptoms are more common in adolescents than in adults taking Invega.
Extrapyramidal symptoms are more common in adolescents than in adults taking Invega.

The recommended starting dose for Invega in adolescents is 3mg once daily given in the morning. For adolescents weighing less than 51kg the maximum daily dose of the atypical antipsychotic is 6mg and for those weighing 51kg or more the dose can be increased to a maximum of 12mg daily. If a dose increase is required it should occur in increments of 3mg daily at intervals of 5 days or more.

Monitoring requirements

Although the safety profile of paliperidone in adolescents is similar to that seen in adults, there is a difference in the frequency of some adverse effects. Sedation, as an effect of paliperidone, should be closely monitored in adolescents. In younger patients it may be advantageous to change the time of administration.

Galactorrhoea occurs more commonly in adolescents than in adults and is suggestive of increased prolactin levels. Prolonged hyperprolactinaemia could affect height, weight, sexual maturation and menstrual functioning; these parameters should be monitored in adolescents taking Invega.

Invega is already indicated for the treatment of schizophrenia and psychotic or manic symptoms of schizoaffective disorder in adults. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases